NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

$11.03 +0.17 (+1.57 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$11.03
Today's Range$10.43 - $11.20
52-Week Range$7.41 - $15.43
Volume170,559 shs
Average Volume398,136 shs
Market Capitalization$277.36 million
P/E Ratio-3.80
Dividend YieldN/A
Beta1.13

About Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals logoSyndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company's product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio8.45%
Quick Ratio8.45%

Price-To-Earnings

Trailing P/E Ratio-3.80
Forward P/E Ratio-3.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.11 million
Price / Sales129.12
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book2.58

Profitability

EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-2,884.34%
Return on Equity-63.51%
Return on Assets-49.23%

Miscellaneous

Employees44
Outstanding Shares24,700,000

How to Become a New Pot Stock Millionaire

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its earnings results on Monday, March, 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.04. The business had revenue of $1.19 million for the quarter, compared to the consensus estimate of $0.75 million. Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. The company's revenue for the quarter was up 290.2% on a year-over-year basis. View Syndax Pharmaceuticals' Earnings History.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

What price target have analysts set for SNDX?

7 brokerages have issued 1 year price objectives for Syndax Pharmaceuticals' stock. Their forecasts range from $20.00 to $40.00. On average, they expect Syndax Pharmaceuticals' share price to reach $26.1667 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.

What are Wall Street analysts saying about Syndax Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (1/23/2018)
  • 2. Cowen Inc analysts commented, "Continued solid progress with ENCORE 601, which combines Entinostat with Keytruda,." (5/9/2017)

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a decline in short interest in March. As of March 29th, there was short interest totalling 967,476 shares, a decline of 42.3% from the March 15th total of 1,676,430 shares. Based on an average trading volume of 352,354 shares, the days-to-cover ratio is presently 2.7 days. Approximately 5.6% of the company's shares are short sold.

Who are some of Syndax Pharmaceuticals' key competitors?

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:
  • Dennis G. Podlesak, Independent Chairman of the Board (Age 59)
  • Michael A. Metzger, President, Chief Operating Officer (Age 45)
  • Briggs W. Morrison M.D., Chief Executive Officer, Director (Age 57)
  • Richard P. Shea, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 64)
  • Michael L. Meyers M.D. Ph.D., Senior Vice President, Chief Development Officer (Age 66)
  • Peter Ordentlich Ph.D., Chief Technology Officer (Age 47)
  • Keith A. Katkin, Director
  • Pierre Legault, Director
  • Henry Chen, Independent Director (Age 45)
  • Fabrice Egros Ph.D., Independent Director (Age 53)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Has Syndax Pharmaceuticals been receiving favorable news coverage?

Press coverage about SNDX stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned news stories about the company an impact score of 45.29 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $11.03.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $277.36 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (SNDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Syndax Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.1667, suggesting that the stock has a possible upside of 137.23%. The high price target for SNDX is $40.00 and the low price target for SNDX is $20.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.1667$26.1667$26.4286$24.2857
Price Target Upside: 137.23% upside116.25% upside189.15% upside122.80% upside

Syndax Pharmaceuticals (NASDAQ:SNDX) Consensus Price Target History

Price Target History for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018Morgan StanleyLower Price TargetOverweight -> Overweight$25.00 -> $24.00HighView Rating Details
1/18/2018B. RileyReiterated RatingBuy$40.00HighView Rating Details
8/14/2017InstinetReiterated RatingBuy$27.00 -> $22.00LowView Rating Details
8/11/2017CitigroupSet Price TargetBuy$24.00 -> $20.00MediumView Rating Details
8/11/2017NomuraLower Price TargetBuy$27.00 -> $22.00MediumView Rating Details
8/11/2017OppenheimerBoost Price TargetOutperform$29.00HighView Rating Details
5/19/2017CowenReiterated RatingOutperformLowView Rating Details
3/16/2017FBR & CoInitiated CoverageOutperform -> Outperform$27.00HighView Rating Details
12/30/2016BTIG ResearchInitiated CoverageBuy$25.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/7/2016GuggenheimInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings History and Estimates Chart

Earnings by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.74)
2019 EPS Consensus Estimate: ($1.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.20)($0.89)($1.05)
Q2 20182($1.04)($0.79)($0.92)
Q3 20182($1.04)($0.72)($0.88)
Q4 20182($1.14)($0.66)($0.90)
Q1 20191($0.48)($0.48)($0.48)
Q2 20191($0.46)($0.46)($0.46)
Q3 20191($0.44)($0.44)($0.44)
Q4 20191($0.42)($0.42)($0.42)

Syndax Pharmaceuticals (NASDAQ SNDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.72)N/AView Earnings Details
3/5/2018Q4 2017($0.76)($0.80)$0.75 million$1.19 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.80)($0.68)$0.30 million$0.31 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.79)($0.70)$0.31 million$0.31 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.74)($0.71)$0.31 million$0.31 millionViewListenView Earnings Details
3/2/2017Y 2016($0.70)($0.59)$0.31 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.81)($0.84)$0.31 millionViewN/AView Earnings Details
8/9/2016Q216($0.54)($0.47)$0.31 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($2.85)$0.31 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Syndax Pharmaceuticals (NASDAQ:SNDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.10%
Institutional Ownership Percentage: 69.55%
Insider Trading History for Syndax Pharmaceuticals (NASDAQ:SNDX)
Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Peter OrdentlichInsiderSell7,500$15.00$112,500.00View SEC Filing  
5/17/2017Peter OrdentlichInsiderSell5,000$15.00$75,000.005,000View SEC Filing  
3/8/2016Ivor RoystonDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines

Source:
DateHeadline
ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"
www.americanbankingnews.com - April 20 at 12:45 PM
Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 2:58 PM
Syndax Pharmaceuticals (SNDX) Downgraded by ValuEngineSyndax Pharmaceuticals (SNDX) Downgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
Syndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreetSyndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreet
www.americanbankingnews.com - April 17 at 8:17 AM
Syndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short InterestSyndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 15 at 1:14 AM
Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...
www.prnewswire.com - April 11 at 4:39 PM
Syndax Pharmaceuticals (SNDX) Downgraded by BidaskClubSyndax Pharmaceuticals (SNDX) Downgraded by BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 6 at 10:54 PM
Syndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per ShareSyndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - April 4 at 11:10 PM
Syndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by BrokeragesSyndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 5:36 AM
Peter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) StockPeter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) Stock
www.americanbankingnews.com - April 3 at 10:46 PM
Syndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:48 PM
Syndax Pharmaceuticals (SNDX) Raised to "Hold" at BidaskClubSyndax Pharmaceuticals (SNDX) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 26 at 10:59 PM
Syndax Pharmaceuticals (SNDX) Upgraded at BidaskClubSyndax Pharmaceuticals (SNDX) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Syndax Pharmaceuticals (SNDX) Upgraded to "Sell" by ValuEngineSyndax Pharmaceuticals (SNDX) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 21 at 12:14 AM
 Analysts Anticipate Syndax Pharmaceuticals Inc (SNDX) Will Announce Earnings of -$1.02 Per Share Analysts Anticipate Syndax Pharmaceuticals Inc (SNDX) Will Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - March 18 at 9:10 PM
Here's Why Syndax Pharmaceuticals Is Soaring TodayHere's Why Syndax Pharmaceuticals Is Soaring Today
finance.yahoo.com - March 14 at 4:41 PM
Syndax Pharmaceuticals (SNDX) Price Target Lowered to $24.00 at Morgan StanleySyndax Pharmaceuticals (SNDX) Price Target Lowered to $24.00 at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:12 AM
Syndax Pharmaceuticals Inc (SNDX) Receives Consensus Rating of "Buy" from AnalystsSyndax Pharmaceuticals Inc (SNDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 5:27 AM
Syndax Pharmaceuticals Inc (SNDX) to Post Q1 2018 Earnings of ($1.20) Per Share, Oppenheimer ForecastsSyndax Pharmaceuticals Inc (SNDX) to Post Q1 2018 Earnings of ($1.20) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 9 at 7:26 AM
B. Riley Equities Analysts Lower Earnings Estimates for Syndax Pharmaceuticals Inc (SNDX)B. Riley Equities Analysts Lower Earnings Estimates for Syndax Pharmaceuticals Inc (SNDX)
www.americanbankingnews.com - March 8 at 6:31 AM
B. Riley Comments on Syndax Pharmaceuticals Incs Q1 2019 Earnings (SNDX)B. Riley Comments on Syndax Pharmaceuticals Inc's Q1 2019 Earnings (SNDX)
www.americanbankingnews.com - March 7 at 1:28 PM
Syndax Pharmaceuticals (SNDX) Posts  Earnings Results, Misses Expectations By $0.04 EPSSyndax Pharmaceuticals (SNDX) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 6 at 8:30 AM
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - March 5 at 4:49 PM
Syndax Pharmaceuticals Inc (NASDAQ:SNDX): Does The -16.61% Earnings Decline Make It An Underperformer?Syndax Pharmaceuticals Inc (NASDAQ:SNDX): Does The -16.61% Earnings Decline Make It An Underperformer?
finance.yahoo.com - March 5 at 10:21 AM
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor ConferencesSyndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
finance.yahoo.com - March 5 at 10:21 AM
Critical Comparison: Syndax Pharmaceuticals (SNDX) & Opiant Pharmaceuticals (OPNT)Critical Comparison: Syndax Pharmaceuticals (SNDX) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - March 5 at 5:14 AM
Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018
finance.yahoo.com - February 26 at 9:36 AM
Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual MeetingSyndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - February 22 at 9:11 AM
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on WednesdaySyndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 3:00 AM
Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Horizon Therapeutics (HPTX)Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Horizon Therapeutics (HPTX)
www.americanbankingnews.com - February 15 at 7:20 PM
Syndax Pharmaceuticals Inc (SNDX) Receives Average Recommendation of "Buy" from BrokeragesSyndax Pharmaceuticals Inc (SNDX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 5:40 AM
Syndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZenecaSyndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
www.streetinsider.com - February 2 at 3:26 PM
Syndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - StreetInsider.comSyndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - StreetInsider.com
www.streetinsider.com - February 2 at 6:28 AM
Pre-Open Movers 02/01: (OPGN) (AFMD) (ICPT) Higher; (EGOV) (ONCS) (UPS) Lower (more...)Pre-Open Movers 02/01: (OPGN) (AFMD) (ICPT) Higher; (EGOV) (ONCS) (UPS) Lower (more...)
www.streetinsider.com - February 1 at 3:24 PM
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZenecaSyndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
finance.yahoo.com - February 1 at 3:24 PM
Syndax Pharmaceuticals Inc (SNDX) Sees Significant Increase in Short InterestSyndax Pharmaceuticals Inc (SNDX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:06 AM
Critical Contrast: Peregrine Pharmaceuticals (CDMO) & Syndax Pharmaceuticals (SNDX)Critical Contrast: Peregrine Pharmaceuticals (CDMO) & Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 25 at 9:48 AM
Syndax Pharmaceuticals (SNDX) Downgraded to "Hold" at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 11:48 AM
Comparing Syndax Pharmaceuticals (SNDX) & Strongbridge Biopharma (SBBP)Comparing Syndax Pharmaceuticals (SNDX) & Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - January 22 at 3:28 AM
Syndax Pharmaceuticals Inc (SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSyndax Pharmaceuticals Inc (SNDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 19 at 5:52 AM
Syndax Pharmaceuticals (SNDX) Rating Reiterated by B. RileySyndax Pharmaceuticals (SNDX) Rating Reiterated by B. Riley
www.americanbankingnews.com - January 18 at 7:00 PM
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
finance.yahoo.com - January 16 at 11:05 AM
Critical Comparison: VIVUS (VVUS) and Syndax Pharmaceuticals (SNDX)Critical Comparison: VIVUS (VVUS) and Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 10 at 7:46 PM
Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast CancerSyndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
finance.yahoo.com - January 10 at 11:09 AM
Financial Contrast: Catalyst Biosciences (CBIO) versus Syndax Pharmaceuticals (SNDX)Financial Contrast: Catalyst Biosciences (CBIO) versus Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 9 at 9:38 AM
Zacks Investment Research Lowers Syndax Pharmaceuticals (SNDX) to SellZacks Investment Research Lowers Syndax Pharmaceuticals (SNDX) to Sell
www.americanbankingnews.com - January 7 at 9:10 AM
Syndax Pharmaceuticals (SNDX) Receives New Coverage from Analysts at B. RileySyndax Pharmaceuticals (SNDX) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - January 6 at 11:50 PM
Syndax Pharmaceuticals (SNDX) & Baxalta (BXLT) Head to Head ReviewSyndax Pharmaceuticals (SNDX) & Baxalta (BXLT) Head to Head Review
www.americanbankingnews.com - December 30 at 3:28 AM
ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 2:38 PM

SEC Filings

Syndax Pharmaceuticals (NASDAQ:SNDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syndax Pharmaceuticals (NASDAQ SNDX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.